clinical-trial
(2)
Basking Biosciences, Inc.
Basking Biosciences is a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapy for acute ischemic stroke. Its lead candidate, BB-031, is a first-in-class RNA aptamer that inhibits von Willebrand Factor to break up clots quickly, paired with a companion reversal agent, BB-025, that can switch the drug's activity off in minutes if bleeding occurs. Spun out of research begun at Duke University and founded in 2019, the company is based in the Research Triangle of North Carolina and is advancing BB-031 through a Phase 2 RAISE trial.
Kara Egan
Kara Egan is the co-founder and CEO of Teal Health, the San Francisco-based company behind the Teal Wand - the first and only FDA-authorized at-home self-collection device for cervical cancer screening in the United States. A Stanford engineer-turned-Wharton MBA, Kara spent years as a venture capital investor at Emergence Capital and .406 Ventures before betting on a product she believed could remake an 80-year-old medical process. Backed by $23M from investors including Emerson Collective, Serena Ventures, and Forerunner, Teal Health has rapidly expanded nationwide with a device that studies show is just as accurate as in-clinic screening and preferred by 94% of women who tried it.